Novo Nordisk A/S (Novo) will carry out a share split whereby every share will be replaced by two new shares (2:1). OMX Derivatives Markets has carried out a re-calculation of options and futures in Novo.
As a result of the adjustment the number of contracts has increased whereas exercise and future prices have decreased. New exercise and futures prices have been be rounded off to two decimal places and received an ”X” in the series designation. The series have also received new ISIN codes, please see attached file.
